EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib

Takeshi Terashima iD, Hidenori Kido, Noboru Takata, Tomoyuki Hayashi, Akihiro Seki iD, Hidetoshi Nakagawa iD, Kouki Nio iD, Tadashi Toyama iD, Noriho Iida, Shinya Yamada, Tetsuro Shimakami, Hajime Takatori und 4 weitere

Cancers · 16.01.2025 · 17 (2) · 278

DOI: 10.3390/cancers17020278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 16.01.2025. Verfasst von Takeshi Terashima und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Atezolizumab and bevacizumab combination therapy has been established as a standard of care for first-line treatment; however, its efficacy and safety have not been fully evaluated for patients previously treated with systemic therapy.

Methods

In this phase II trial, patients with advanced hepatocellular carcinoma previously treated with lenvatinib were enrolled to receive a dose of 1,200 mg of atezolizumab and 15 mg/kg of bevacizumab every 3 weeks. The primary endpoint was progression-free survival. The secondary endpoints included overall survival, objective response rate, disease control rate, subsequent therapy, and frequency of adverse events. The threshold and expected progression-free survival were 3 and 6.8 months, respectively. Considering a one-sided significance level of 0.05 and a statistical power of 80%, the minimum required sample size was 26 patients.

Results

The median progression-free survival from the start of treatment was 9.70 [90% confidence interval, 5.10–14.24] months, and the lower limit of the 90% CI was above the predefined threshold. The objective response and disease control rates were 34.6% and 73.1%, respectively. Sixteen patients (61.5%) received subsequent therapies, and the median overall survival was 17.23 [90% confidence interval, 13.18–27.85] months. Severe adverse events, adverse events leading to treatment delays, and adverse events leading to treatment discontinuation occurred in eight (30.8%), fourteen (53.8%), and five (19.2%) patients, respectively, and no treatment-related deaths occurred.

Conclusions

Atezolizumab and bevacizumab combination therapy is effective and can safely be administered to patients with advanced HCC previously treated with lenvatinib.

Schlagwörter

Stichwörter der Autor:innen

atezolizumabbevacizumabhepatocellular carcinomasecond-line treatment

Autor:innen und Institutionen

  • Department of Gastroenterology, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan.
  • Department of Nephrology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1104, Fukui, Japan.

ORCID-Profile: Takeshi Terashima, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Tadashi Toyama, Taro Yamashita

Zitieren

APA

Terashima, T., Kido, H., Takata, N., Hayashi, T., Seki, A., Nakagawa, H., Nio, K., Toyama, T., Iida, N., Yamada, S., Shimakami, T., Takatori, H., Arai, K., Yamashita, T., Mizukoshi, E., & Yamashita, T. (2025). Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib. Cancers, 17(2), 278. https://doi.org/10.3390/cancers17020278

Vancouver

Terashima T, Kido H, Takata N, Hayashi T, Seki A, Nakagawa H, et al. Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib. Cancers. 2025;17(2):278. doi:10.3390/cancers17020278

BibTeX
@article{Terashima2025,
  author = {Terashima, Takeshi and Kido, Hidenori and Takata, Noboru and Hayashi, Tomoyuki and Seki, Akihiro and Nakagawa, Hidetoshi and Nio, Kouki and Toyama, Tadashi and Iida, Noriho and Yamada, Shinya and Shimakami, Tetsuro and Takatori, Hajime and Arai, Kuniaki and Yamashita, Tatsuya and Mizukoshi, Eishiro and Yamashita, Taro},
  title = {Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {2},
  pages = {278},
  doi = {10.3390/cancers17020278}
}
Kostenlos starten →